|
[1]WHO.Global hepatitis report 2017[EB/OL]. (2017-08-20) .http://www.who.int/hepatitis/publications/globalhepatitisreport 2017/en/.
|
|
[2]GOWER E, ESTES C, BLACH S, et al.Global epidemiology and genotype distribution of the hepatitis C virus infection[J].J Hepatol, 2014, 61 (1) :45-57.
|
|
[3]INDOLFI G, HIERRO L, DEZSOFI A, et al.Treatment of chronic hepatitis C virus infection in children.A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition[J].J Pediatr Gastroenterol Nutr, 2018, 66 (3) :505-515.
|
|
[4]INDOLFI G, THORNE C, SAYED MH, et al.The challenge of treating children with hepatitis C virus infection[J].J Pediatr Gastroentero Nutr, 2017, 64 (6) :851-854.
|
|
[5]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment of hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[6]CHENG DY, LIU XM, OU WN, et al.Clinical efficacy of directacting antiviral agents in patients with HCV-related liver cirrhosis[J].Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (6) :545-549. (in Chinese) 程丹颖, 刘晓民, 欧蔚妮, 等.直接抗病毒药物治疗丙型肝炎肝硬化患者的疗效观察[J].中华实验和临床感染病杂志:电子版, 2017, 11 (6) :545-549.
|
|
[7]BALISTRERI WF, MURRAY KF, ROSENTHAL P, et al.The safety and effectiveness of ledipasvir sofosbuvir in adolescents 12-17years old with hepatitis C virus genotype 1 infection[J].Hepatology, 2017, 66 (2) :371-378.
|
|
[8]WIRTH S, ROSENTHAL P, GONZALEZ-PERALTA RP, et al.Sofosbuvir and ribavirin in adolescents 12 to 17 years old with hepatitis C virus genotype 2 or 3 infection[J].Hepatology, 2017, 66 (4) :1102-1110.
|
|
[9]The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present.HCV guidance:recommendations for testing, managing, and treating hepatitis C[S/OL]. (2017-09-21) .http://www.Hcvguidelines.org.
|
|
[10]NAN YM, LI DD, KONG LB.Focus on the treatment of chronic hepatitis C in children[J].J Clin Hepatol, 2018, 34 (2) :246-250. (in Chinese) 南月敏, 李冬冬, 孔令波.关注儿童慢性丙型肝炎的治疗[J].临床肝胆病杂志, 2018, 34 (2) :246-250.
|
|
[11]MURRAY KF, BALISTRERI W, BANSAL S, et al.Ledipasvir/sofosbuvir±ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infection[J].J Hepatol, 2017, 66 (1) :57-58.
|
|
[12]XIE L, HAO P, WU RH, et al.Establishment and application of a database for hepatitis C virus NS3/4A protease inhibitors and their drug resistance data[J].J Clin Hepatol, 2018, 34 (8) :1884-1890. (in Chinese) 谢磊, 郝沛, 吴瑞红, 等.HCV NS3/4A蛋白酶抑制剂药物及其耐药信息数据库的建立和应用[J].临床肝胆病杂志, 2018, 34 (8) :1884-1890.
|
DownLoad: